中智全球(06819.HK)因一項針對公司電郵系統的社交工程罪行而未經授權發放資金700萬美元
格隆匯7月12日丨中智全球(06819.HK)發佈公吿,於2021年6月29日及7月5日,公司因一項針對公司電郵系統的社交工程罪行而蒙受損失。因此,合共700萬美元已發放予與公司並無聯繫的多個銀行賬户。公司的調查仍在進行中,而此時公司系統的初步取證掃描已識別出有一個單一電郵賬户遭動用,並使用偽造文件等方法發出國際電匯的欺詐指示。
公司於2021年7月8日就該未經授權發放向香港及台灣警方報案,並於2021年7月9日向美國聯邦調查局網絡犯罪投訴中心(IC3–Internet Crime Complaint Center)報案,該未經授權發放現正處於調查階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.